Qualifying Conditions for Medical Cannabis in the United States: Ultimate Guide

A medical condition can qualify someone for a state cannabis program without proving that cannabis is an effective treatment for that condition. Eligibility rules, clinician judgment and medical evidence answer different questions. This guide explains commonly discussed conditions and how to check the rules that apply where you live.

There is no single national list or universal medical-marijuana card process. Some programs use a defined list, others allow broader clinician discretion, and some permit adult self-certification. A diagnosis alone does not guarantee registration, access to a particular product or permission to grow cannabis.

Federal Status and FDA Approval

The April 28, 2026 federal rule moved covered FDA-approved marijuana drug products and marijuana subject to specified state medical licenses to Schedule III. It also established federal registration requirements. This was not blanket legalization of every cannabis product or activity, and it did not make every dispensary product FDA-approved.

The FDA has approved specific cannabinoid medicines for specific indications. State authorization is a different process from the FDA drug-approval process. Our regulation coverage tracks legal developments, while the treating clinician should assess evidence and alternatives.

Examples of How Eligibility Differs

• Florida uses qualifying conditions and related statutory categories, physician certification and registry identification requirements.
• New York allows certification based on a practitioner’s assessment of benefit for the patient’s condition, rather than a closed list of diagnoses.
• Washington, DC allows adults 21 and older to self-certify for medical-cannabis registration. Younger patients have different requirements.
• Texas uses qualified physicians and the electronic Compassionate Use Registry. Patients do not apply for a conventional state medical-marijuana card, and the program requires permanent Texas residency.

These examples illustrate different systems; they are not a substitute for checking your own program. The following conditions are a discussion guide, not a claim that all 24 qualify in every state.

1. Chronic Pain

Some states accept chronic, severe or intractable pain, but their definitions differ. AHRQ’s 2025 review found small short-term improvements with some THC-containing products, alongside increased adverse effects. Oral CBD alone did not improve pain or function versus placebo. Eligibility does not establish that cannabis will replace opioids or prevent overdose.

2. Cancer-related Symptoms

Cancer may qualify a patient, but cannabis is not an established cancer treatment. NCI’s evidence review distinguishes symptom management from anticancer effects. Prescription dronabinol and nabilone have chemotherapy-related nausea indications; that evidence cannot be transferred to every dispensary product or ordinary CBD oil.

3. Multiple Sclerosis (MS)

MS and persistent muscle spasticity appear in several programs. Certain cannabinoid preparations may modestly improve patient-reported spasticity, but are not disease-modifying MS treatments. The NCCIH evidence summary emphasizes product-specific benefits and limitations.

4. Glaucoma

Glaucoma’s inclusion in a legal list does not make cannabis a suitable treatment. The ophthalmology guidance does not recommend it: pressure reduction is brief and evidence of protection against disease progression is lacking. Continue the treatment plan established with an eye specialist.

5. Epilepsy and Other Seizure Disorders

Seizure disorders may qualify under state rules. Separately, Epidiolex is FDA-approved for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome or tuberous sclerosis complex in patients aged one year and older. That approval applies to the prescription medicine, not retail CBD generally.

6. Post-Traumatic Stress Disorder (PTSD)

PTSD qualifies in several jurisdictions, but legal eligibility and treatment recommendations differ. The VA/DoD guideline recommends against cannabis or cannabis derivatives for PTSD because efficacy is unproven and risks are established. Evidence-based PTSD care should remain central.

7. HIV/AIDS

HIV/AIDS is included in many programs. Prescription dronabinol has an indication for AIDS-related anorexia with weight loss; this does not establish that cannabis treats HIV or replaces antiretroviral therapy. Symptom management and medication interactions need individualized assessment.

8. Crohn’s Disease and Inflammatory Bowel Disease (IBD)

Some programs recognize Crohn’s disease or IBD. The Crohn’s & Colitis Foundation distinguishes possible symptom relief from disease control: current evidence does not establish reduced bowel inflammation or improved disease activity. Feeling less pain is not proof that inflammation is controlled.

9. Parkinson’s Disease

Parkinson’s disease may meet a state’s criteria. The Parkinson’s Foundation reports no conclusive evidence of benefit and no demonstrated human neuroprotective effect. Cannabis should not replace established Parkinson’s medicines.

10. Amyotrophic Lateral Sclerosis (ALS)

ALS or its associated spasticity may qualify. Research into symptom relief remains limited; it does not establish that cannabis slows ALS progression. Decisions should be made within the person’s neurological and supportive-care plan.

11. Alzheimer’s Disease

Some programs include Alzheimer’s disease, sometimes with symptom-specific criteria. Evidence does not show that cannabis or CBD slows, prevents or reverses dementia. Research on agitation is a separate question and does not demonstrate a cure or disease modification.

12. Fibromyalgia

Fibromyalgia may qualify by name or through a state’s pain criteria. Cannabis evidence remains limited and does not justify promising improved function or an opioid substitute. Assess sleep, activity and pain together rather than treating a short-term pain score as the only outcome.

13. Arthritis

Arthritis may fall under a qualifying pain category. The Arthritis Foundation describes limited and mixed CBD evidence. Symptom reports do not show that CBD prevents joint damage or replaces disease-modifying treatment for inflammatory arthritis.

14. Migraines

Migraine eligibility depends on the program. A randomized trial published in 2026 found benefit from a particular vaporized THC-plus-CBD preparation for acute attacks. This does not establish that CBD alone prevents migraines or that all commercial products have the same effect.

15. Neuropathic Pain

Neuropathic pain is prominent in cannabinoid research and may qualify under pain rules. AHRQ found modest short-term benefits for certain preparations, with dizziness, sedation and nausea among the tradeoffs. Results do not apply uniformly to every cause of nerve pain or every formulation.

16. Anorexia and Eating Disorders

Appetite loss and wasting are not the same diagnosis as anorexia nervosa. A legal provision for anorexia must be read in its clinical and statutory context. Appetite stimulation alone does not treat an eating disorder’s psychological, nutritional or medical complications.

17. Chronic Nausea and Vomiting

Severe nausea may qualify, but the cause matters. Cannabis can also cause cannabinoid hyperemesis syndrome, with recurrent vomiting and abdominal pain. Repeated vomiting in someone using cannabis needs evaluation rather than an assumption that taking more will help.

18. Tourette Syndrome

Tourette syndrome appears in some state lists. Small studies of cannabinoids for tics are insufficient to establish routine use for everyone with Tourette syndrome. Eligibility should lead to a discussion of alternatives and adverse effects, not automatic treatment.

19.  Anxiety Disorders

Anxiety is not a universal qualifying condition. CBD research does not establish retail cannabis as an effective treatment for anxiety disorders, and THC can worsen anxiety. The American Psychiatric Association’s position does not endorse cannabis as medicine for psychiatric disorders.

20. Depression

Depression should not be presented as an established cannabis indication. Evidence does not support replacing antidepressant treatment or psychotherapy with cannabis. Where a program allows practitioner discretion, legal access still requires a separate clinical judgment about benefit and risk.

21. Insomnia

Insomnia may qualify in a discretionary program or alongside another condition. Research findings often concern sleep symptoms in other illnesses, rather than primary insomnia. Short-term sedation is not proof of durable sleep improvement, and withdrawal can disrupt sleep.

22. Autism Spectrum Disorder (ASD)

Autism is included in some legal programs, but evidence remains insufficient for routine treatment of core symptoms or associated behavior. AACAP advises against medical marijuana for these purposes in children and adolescents. Pediatric eligibility requires the applicable specialist, caregiver and program safeguards.

23. Cachexia or Wasting Syndrome

Cachexia or wasting may qualify, but appetite gain is not equivalent to restoring muscle or reversing the underlying disease. The strongest prescription-cannabinoid indication here concerns AIDS-related anorexia with weight loss; broader cachexia claims require caution.

24. Opioid Use Disorder

Some jurisdictions include opioid-related eligibility pathways. Cannabis is not an established replacement for FDA-approved opioid-use-disorder medications: buprenorphine, methadone and naltrexone. Do not stop effective addiction treatment on the basis of a medical-cannabis qualification.

How to Check Eligibility and Obtain Access

1. Start with the official program. Check residency, age, qualifying-condition language, caregiver rules and whether the program is accepting patients and dispensing products.
2. Arrange the appropriate evaluation. Where required, use an authorized practitioner and bring relevant medical records and your medication list. Self-certification is available only where the jurisdiction permits it.
3. Complete the local process. This may involve certification, a registry entry, an application, identification and a fee. Do not assume every program issues a physical card or charges a patient fee.
4. Use an authorized seller. Follow the program’s product, quantity and dispensing restrictions. A medical registration does not authorize every hemp product, every route of administration or home cultivation.
5. Track reassessment and renewal. Practitioner certification, patient registration and purchase authorization may have different expiration dates. Discuss whether the treatment is meeting measurable goals.

Questions for the Clinical Review

Ask which symptom is being targeted, what evidence supports the particular product, how success will be measured and when to stop if benefit is absent. Review other medicines, impairment, falls, mental-health history and the risk of problematic use. Children, pregnancy and breastfeeding require particular care. Avoid driving while impaired.

A qualifying condition is an entry point to a decision, not a promise of relief. Treatment should support the person’s overall care and should not delay effective therapy for the underlying disease.